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Abstract Hypoxia-inducible factor (HIF-1) is the key
transcription regulator for multiple angiogenic factors and
is an appealing target. Ginsenoside-Rg1, a nontoxic sapo-
nin isolated from the rhizome of Panax ginseng, exhibits
potent proangiogenic activity and has the potential to be
developed as a new angiotherapeutic agent. However, the
mechanisms by which Rg1 promotes angiogenesis are not
fully understood. Here, we show that Rg1 is an effective
stimulator of HIF-1a under normal cellular oxygen condi-
tions in human umbilical vein endothelial cells. HIF-1a
steady-state mRNA was not affected by Rg1. Rather, HIF-1a
protein synthesis was stimulated by Rg1. This effect was
associated with constitutive activation of phosphatidylino-
sitol 3-kinase (PI3K)/Akt and its effector p70 S6 kinase
(p70
S6K), but not extracellular-signal regulated kinase 1/2.
We further revealed that HIF-1a induction triggered the
expression of target genes, including vascular endothelial
growth factor (VEGF). The use of small molecule inhibi-
tors LY294002 or rapamycin to inhibit PI3K/Akt and
p70
S6K activities, respectively, resulted in diminished HIF-
1a activation and subsequent VEGF expression. RNA
interference-mediated knockdown of HIF-1a suppressed
Rg1-induced VEGF synthesis and angiogenic tube
formation, conﬁrming that the effect was HIF-1a speciﬁc.
Similarly, the angiogenic phenotype could be reversed by
inhibition of PI3K/Akt and p70
S6K. These results deﬁne a
hypoxia-independent activation of HIF-1a, uncovering a
novel mechanism for Rg1 that could play a major role in
angiogenesis and vascular remodeling.
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Introduction
Insufﬁcient angiogenesis is a major pathological component
of diseases such as chronic wounds and ischemic heart dis-
ease. Therapeutic angiogenesis aims at solving this problem
by stimulating new vessel formation [1]. Given its central
role in angiogenesis, vascular endothelial growth factor
(VEGF) has become a prime target for angiotherapy. How-
ever,clinicaltrialshavenotachievedsatisfactoryresultsdue
toaberrant functionsof the overexpressed protein. Hypoxia-
inducible factor-1 (HIF-1), which can stimulate the required
angiogenic growth factors endogenously, has been sug-
gested to provide an advantage over VEGF therapy [2].
Hypoxia-inducible factor is a master regulator of the
transcriptional response of angiogenesis [3]. HIF-1 is a het-
erodimer consisting of subunits HIF-1a and HIF-1b [4].
HIF-1b is constitutively expressed, whereas HIF-1a is
tightly regulated by changes in oxygen regimes [5, 6]. HIF-
1a expression is regulated by multiple mechanisms.
Although it primarily involves protein ubiquitination, the
accumulationofHIF-1ahasalsobeenshowntodependonits
rate of de novo protein synthesis [7]. Depending on the cell
types and stimuli, different signaling pathways are involved
in regulation of HIF-1a expression. Once activated, HIF-1
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DOI 10.1007/s10456-011-9235-zregulates a repertoire of key angiogenic genes, including
VEGF, platelet-derived growth factor (PDGF), and trans-
forming growth factor a (TGFa)[ 3]. Thus, HIF-1 represents
an appealing drug target. Nevertheless, targeted therapy in
clinical settings, in general, is not sufﬁcient to treat angio-
genic diseases, partly due to inadequate delivery strategies
[8]. Plant-based small molecule activators that exhibit low
toxicity and side effects hold promise as new treatment
options.
Emerging evidence shows that nonpeptide small mole-
cules, such as saponins, can modulate angiogenesis, with
great potential to be developed as angiotherapeutic agents
[9]. Panax ginseng, containing saponins as the major and
biological active components, is a key herb in traditional
Chinese medicine reported to be efﬁcacious in treating
diabetes and cardiovascular concerns, and its consumption
is safe and nontoxic, even at high doses in animals and
humans [10]. A notable saponin isolated from P. ginseng is
Rg1 [11]. We have previously shown strong proangiogenic
efﬁcacy of Rg1. In particular, Rg1 was found to potently
promote human umbilical vein endothelial cell (HUVEC)
proliferation, chemoinvasion, and tube formation in vitro,
to stimulate neovascularization in vivo, and to induce
outgrowth of aortic sprout ex vivo [12]. Given this poten-
tial as a new attractive modality for angiotherapy, it is of
great interest to characterize the signal transduction path-
way whereby Rg1 contributes to angiogenesis.
We have used HUVECs based on its ability to undergo
in vitro angiogenesis in response to appropriate stimuli but
also a standard line for angiogenic screening to provide
understanding of the mechanisms of Rg1. Using this
model, we show for the ﬁrst time that Rg1 is a potent
stimulator of HIF-1a under normal oxygen conditions. We
also provide mechanistic insights suggesting that the acti-
vation of the translation signal, especially p70
S6K through
the PI3K/Akt mediated pathway in this process. This
hypoxia-independent activation of HIF-1a elucidates an
important mechanism, which may explain the promising
effects of Rg1 on angiogenesis and provide a rationale for
the development of Rg1 as a new source of small molecule
angiomodulator.
Materials and methods
Cell culture and reagents
Human umbilical vein endothelial cells were obtained from
Clonetics (San Diego, CA) and cultured in medium 199
supplemented with 20% fetal bovine serum, 20 lg/ml
endothelial cell growth supplement, 90 U/ml heparin,
and 1% penicillin–streptomycin in a humidiﬁed incubator
at 37C with 5% CO2. The ﬁfth to eighth passages of
HUVECs were used in these studies to ensure genetic
stability of the culture. Ginsenoside-Rg1 is a reference
compound (purity[98%) purchased from the Division of
Chinese Material Medica and Natural Products, National
Institute for the Control of Pharmaceutical and Biological
Products, Ministry of Public Health, China. A stock
solution of Rg1 (50 mM) was prepared in sterile double
distilled water.
Western blotting
Cells were lysed in RIPA buffer (150 mM NaCl, 50 mM
Tris pH 7.4, 2 mM EDTA, 0.2% SDS, and 1% Triton
X-100). Lysates were cleared by centrifugation, and pro-
tein concentrations were determined using the Bradford
method with reagents from Bio-Rad (Hercules, CA). Equal
amounts of cell lysates were separated by SDS–PAGE and
transferred to a nitrocellulose membrane. The blot was then
probed with HIF-1a and HIF-1b (BD Transduction Labo-
ratories, San Jose, CA; 1:500), VEGF (Santa Cruz Bio-
technology, Santa Cruz, CA; 1:1,000), phospho-Akt,
total Akt, phospho-p70
S6K, total p70
S6K (Cell Signaling,
Danvers, MA; 1:1,000), and b-actin (Sigma, St. Louis,
MO; 1:1,000) followed by reaction with horseradish per-
oxidase-conjugated secondary antibody. The signal was
detected using enhanced chemiluminescence (Amersham,
Piscataway, NJ).
Small interfering RNA
The ON-TARGET plus SMARTpool small interfering
RNA (siRNA) for human HIF-1a (L-040638-00) and
nontargeting control (D-001810-10) were purchased from
Dharmacon (Lafayette, CO). siRNA oligonucleotides
(10 nM) were transfected into cells with siLentfect reagent
(Bio-Rad, Hercules, CA). After 24 h of transfection,
Western blotting was carried out to examine the knock-
down of targeted proteins.
Reverse transcription–PCR
Total RNA isolated using Trizol (Invitrogen, Carlsbad, CA)
was reverse transcribed with the SuperScript II reverse
transcriptase (Invitrogen) using an oligo-dT primer accord-
ingtothemanufacturer’sprotocol.ThecDNAwassubjected
to PCR ampliﬁcation using the following forward and
reverse primer sets: HIF-1a,5 0-CGTTGTGAGTGGTATT
ATTCA GCA-30 and 50-CAGTTTCTGTGTCGTTGCTG
CC-30; HIF-1b,5 0-CTGCTCTG TTGCCTCTCTAA-30 and
50-TTCTCCTCTCCTCCACTCTC-30; glyceraldehydes-3-
phosphate dehydrogenase (GAPDH), 50-CGGAGTCAAC
GGATTTGGTCGTAT-30 and 50-AGCCTTCTCCATGGT
GGTGAAGAC-30.PCRconditionswereestablishedinpilot
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123experiments to ensure linear reaction rates. GAPDH was
used as the internal standard. PCR products were separated
on 1.5% agarose gels and visualized by ethidium bromide
staining. Gels were photographed using Gel DOC 2000
(Bio-Rad, Hercules, CA).
Capillary tube formation assay
HUVECs (1 9 10
5 cells) were seeded on a growth factor-
reduced Matrigel-coated 24-well plate (BD Biosciences, San
Jose, CA) in the presence or absence of Rg1 or with a com-
bination of Rg1 and various small molecule inhibitors or
HIF-1asiRNA.After6 hofincubation,imageswerecaptured
using a phase-contrast microscope (109) using a CCD cam-
era. The degree of tube formation was quantiﬁed by counting
thenumberoftube-likestructuresin4randomlychosenﬁelds
randomly selected for each well without overlap.
Statistical analysis
Data were expressed as the mean ± SD. Comparisons were
made using one-way analysis of variance, with Tukey’s
least signiﬁcant difference t test for post hoc analysis
(GraphPad software, San Diego, CA). Differences were
considered to be statistically signiﬁcant at P\0.05.
Results
Rg1 stimulates HIF-1a accumulation in HUVECs
To investigate whether Rg1 could affect the activity of HIF-
1, we ﬁrst performed time course experiments to examine
HIF-1 protein expression in the absence and presence of
Rg1. As shown in Fig. 1, Rg1 induced a robust accumula-
tion of HIF-1a protein in HUVEC under normoxic condi-
tions, which was clearly detectable after 1 h, and this time
point was used in all subsequent experiments. In contrast,
Rg1 did not change levels of HIF-1b protein (Fig. 1).
Rg1 does not affect HIF-1a mRNA accumulation
but increases its protein synthesis
The rapid induction of HIF-1 suggests that it is likely that
activation is controlled at the posttranscriptional level [5].
We asked whether Rg1 may be acting on HIF-1a produc-
tion. The results of RT-PCR, however, revealed that HIF-
1a mRNA levels remained unchanged by Rg1 treatment
(Fig. 2a), indicating that Rg1 does not affect HIF-1a
mRNA accumulation. Similar results were obtained in
HIF-1b (Fig. 2a). To determine whether Rg1-mediated
increase of HIF-1a was the result of increased protein
synthesis, we utilized the protein synthesis inhibitor
cycloheximide. Figure 2b shows that the inhibition with
cycloheximide greatly decreased the accumulation of
HIF-1a induced by Rg1, suggesting that protein synthesis
is involved in this process.
Rg1 regulates HIF-1a in a PI3K/Akt and p70
S6K-
dependent manner
To determine the signaling pathway involved, HUVECs
were treated with Rg1 for indicated times and the activation
of various signaling molecules were analyzed by Western
blotting using phospho-speciﬁc antibodies. The PI3K/Akt
pathway is implicated in regulation of the translation of
HIF-1a expression [13–15]. To address its involvement in
Rg1-mediated HIF-1a accumulation, we measured the
phosphorylation status of Akt and its effector p70
S6K.
Interestingly, treatment of Rg1 resulted in a time-dependent
phosphorylation of Akt, which correlated with the phos-
phorylation of p70
S6K, and with the induction of HIF-1a
accumulation in HUVEC (Fig. 3). Rg1 did not affect the
total protein levels of these kinases, indicating that this
effect was speciﬁc to protein phosphorylation (Fig. 3). The
activation of p-Akt by Rg1 required the activity of its
upstream regulator PI3K, as the PI3K inhibitor LY294002
blocked this activation. LY294002 also blocked the stim-
ulatory effect of Rg1 on the expression HIF-1a (Fig. 4a).
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Fig. 1 Rg1 regulates HIF-1a protein. HUVECs were treated with Rg1
(150 nM)for0,5,10,15,30,60,120,and240 min.Celllysates(50 lg)
were subjected to immunoblotting with antibody against HIF-1a and
HIF-1b. b-actin was used as a loading control. The signal intensities
were determined by densitometry. Data are shown as mean ± SD of
three independent experiments. *P\0.05, difference with untreated
control
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123We further revealed that HIF-1a induction triggered the
expression of target genes, including VEGF, which one of
the best characterized and most frequent responses to HIF-
1a activation that may have a positive effect on angiogen-
esis function [16]. As shown in Fig. 4a, LY294002
repressed the stimulatory ability of Rg1 upon VEGF
expression. Similarly, the mTOR/p70
S6K inhibitor rapa-
mycin that produced a rapid inhibition of p70
S6K also
reduced the HIF-1a expression and subsequent VEGF
expression (Fig. 4b). Together, these results suggest the
involvement of PI3K/Akt/p70
S6K signaling in the activation
of HIF-1a protein synthesis by Rg1.
Rg1 effects on HIF-1 require glucocorticoid receptor
Rg1 signals have been shown to be transduced via the
glucocorticoid receptor (GR) [17, 18]. RU486, an inhibitor
speciﬁc to GR, signiﬁcantly abrogated Rg1-induced HIF-1a
as well as Akt and p70
S6K phosphorylation, which is a
critical step in Rg1-induced HIF-1a activation, indicating
that GR mediates the action of Rg1 (Fig. 5). In support of
this observation, RU486 also completely aborted the effect
of Rg1 on VEGF expression (Fig. 5).
HIF-1a is involved in Rg-1-induced angiogenic action
in HUVEC
Given that HIF-1a is the key regulator of angiogenesis, we
next analyzed the effect of HIF-1a on Rg1-induced
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1a protein degradation but
increases its protein synthesis.
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Total RNA was isolated, and
RT-PCR was performed using
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S6K signaling.
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123angiogenic function. The tube formation assay was chosen
because it has the advantage over other angiogenic assays,
in which it replicates multiple key steps of the angiogenic
process involving adhesion, migration, differentiation, and
growth [19]. We used siRNA to ablate HIF-1a expression.
Transfection with HIF-1a siRNA, but not nonspeciﬁc
siRNA, revealed a signiﬁcant decrease in HIF-1a protein
level and subsequent VEGF upregulation (Fig. 6a).
Importantly, HIF-1a siRNA-transfected cells exhibited a
discernible reduction in Rg1-induced angiogenic tube for-
mation, indicating that HIF-1a function is required for this
process (Fig. 6b). No inhibitory effect on tube formation
was observed for nonspeciﬁc siRNA. Similarly, inhibition
of PI3K/Akt by LY294002 or inhibition of mTOR/p70
S6K
by rapamycin markedly attenuated Rg1-stimulated tube
formation (Fig. 6c). These data indicate a role for HIF-1a
in the angiogenic activity of Rg1 in HUVEC and that the
effect was mediated via PI3K/Akt and p70
S6K.
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123Discussion
Hypoxia-inducible factor is one of the few genes in which
its genetic deletion is embryonic lethal due to severe vas-
cular abnormalities and thus held great promise as a ther-
apeutic target [20–22]. These studies reveal that expression
of HIF-1 is required for normal development of the heart,
blood vessels, and blood cells, i.e., all three components of
the circulatory system are dependent on HIF-1. Thus,
factors that modulate HIF-1 are attractive modalities for
angiotherapy. Ginseng is listed in the pharmacopoeias of
several countries, including the United States and Europe
and has been widely used throughout the world for
medicinal purposes due to its rich content of saponins
[9, 10]. The present study for the ﬁrst time reported the
functional effect of the naturally occurring saponin Rg1
from P. ginseng as a potent regulator of HIF-1a.
Although it is generally thought that HIF-1 is regulated
mainly by oxygen tension, there is increasing evidence that
a number of nonhypoxic factors also modulate HIF-1
expression and consequent function, for example, growth
factors, cytokines and oncogenic signals [13, 14]. Previous
work has demonstrated that the wound ﬂuid environment is
not hypoxic [23], suggesting that angiogenic growth factor
production at the wound site may be initiated or potentiated
by a factor other than hypoxia. Intriguingly, our studies
suggest that Rg1 may be such a factor for regulating HIF-1.
To our knowledge, such property possessed by Rg1 has not
been reported for other saponins. Thus, it is rational to
explore Rg1 as a source of novel angiogenic modulator.
It is interesting that the mechanisms for HIF-1a acti-
vation under hypoxic and nonhypoxic conditions are
strikingly different. Unlike hypoxia, nonhypoxic stimuli
often do not induce HIF-1a stabilization [24]. We show
that Rg1 is able to increase the rate of HIF-1a protein
synthesis. The PI3K/Akt/mTOR pathway is a key regulator
of protein synthesis [13–15]. p70
S6K, a central serine/
threonine kinase downstream of mTOR, controls protein
translation by enhancing the translation of mRNAs con-
taining 50-terminal oligopyrimidine tract (TOP) sequences
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123in their 50-UTR [25]. Interestingly, the 50-UTR of the
mRNA encoding HIF-1a contains 50-TOP sequences that
can be regulated by p70
S6K activation. We have shown that
treatment of HUVECs with Rg1 increased the phosphory-
lation of p70
S6K, which concomitant with the increase of
HIF-1a expression. A key role of p70
S6K in the regulation
of translation further suggests that Rg1-induced activation
of PI3K/Akt/p70
S6K pathway might be involved in HIF-1a
translation. In this context, it is also interesting to note that
although the effect of Rg1 could also be mediated through
a MAPK pathway and there is evidence that ERK1/2 reg-
ulates HIF-1a function in certain cells [26], we ruled out
this possibility in HUVEC, since treatment of cells with the
ERK1/2 inhibitor PD98059 had no effect on Rg1-mediated
activation of HIF-1a (Supplementary Fig. 1).
The mechanism by which Rg1 activates PI3K/Akt/
p70
S6K signaling is not yet fully understood, but Rg1 has
been shown to be a functional ligand of GR [17, 18]. The
rapid nongenomic effects of GR have been attracted
increasing attention in recent years. Although the underly-
ing mechanism of action is not clear, our recent studies
show that Rg1 can exert its nongenomic effects by cross-
regulation of receptor tyrosine kinases through a
GR-dependent, ligand-independent mechanism [27]. The
presence of membrane-bound GR is highly consistent with
this hypothesis [28, 29]. Together with our previous studies
[27], our data demonstrate that this new mechanism applies
to more genes and can have direct and indirect effects on
gene expression responsible for triggering the rapid onset of
angiogenesis. This notion is consistent with the obvious
protective effects of Rg1 in acute conditions, such as
endothelial dysfunction or myocardial ischemia, where
rapid endothelialization and/or angiogenesis are desirable
[9]. Moreover, given the undesirable side effects from
genomic actions, it is becoming increasingly evident that a
nongenomic action is more beneﬁcial in clinical use to
maximize efﬁcacy and minimize adverse effects or toxicity.
The implication of a dietary saponin affecting the
activity of a pivotal protein such as HIF-1a is intriguing.
While prolonged HIF-1a activation is important, a rapid,
transient stabilization of HIF-1a might produce similar
results on the induction of a stable and healthy vasculature
[30]. HIF-1a has been shown to be required for the
expression of multiple angiogenic genes, including VEGF,
PDGF, and TGFa [3]. This might explain why it is possible
to achieve profound effect in angiogenesis with a low dose
of Rg1. Indeed, the extract from Sanqi ginseng, which as a
predominance of Rg1, is considered the key ingredient for
the treatment of trauma injuries and for promoting micro-
circulation [31]. Since the concentration of Rg1 (150 nM;
0.12 g/l) used in our experiments is within the physiolog-
ical range of the plasma level of Rg1, based on the oral
bioavailability of 3.29–18.4% for Rg1 in animal studies
[32, 33], our ﬁndings are also particularly relevant to
pharmacological approaches.
In summary, the results of this study reveal an important
new mechanism of the proangiogenic activity of Rg1. This
mechanism involves Rg1 activates HIF-1a activity, which
is the starting step of the angiogenic reaction. These data
highlight the importance of developing Rg1 as a new
nonpeptide small molecule-based prototype for therapeutic
angiogenesis, such as in wounding healing, cardiovascular,
and ischemic disease.
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